An open-label, randomized trial was conducted to compare the efficacy and safety of 2 regimens of interferona-2a (IFN-a-2a) plus ribavirin for management of chronic hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-coinfected patients. Sixty-eight patients were randomized to receive IFN-a-2a at a dosage of either (1) 6 MU given 3 times per week for 24 weeks, followed by 3 MU 3 times per week for an additional 24 weeks (group A; 31 patients); or (2) 9 MU per day for 2 weeks, followed by 3 MU per day for 22 weeks, followed by 3 MU 3 times per week for 24 weeks (group B; 37 patients). Ribavirin was added at week 16 of therapy if HCV RNA remained detectable at week 12. Sustained virological response was achieved in 10 patients (15%; 6 in group A and 4 in group B). HCV genotypes 2 or 3 and a decrease in the HCV load of у3 log 10 copies/mL between inclusion and week 4 were associated with virological response. In conclusion, the combination of conventional IFN-a-2a and ribavirin has poor virological efficacy in HCV-HIV-coinfected patients.
infection with an accelerated progression to cirrhosis [4] , and HCV-HIV-coinfected patients are at higher risk for developing hepatotoxicity associated with HAART [5] . On the other hand, HCV coinfection has also been reported to alter immune recovery during HAART [6] . Consequently, stabilized patients receiving HAART should now be considered for treatment of chronic hepatitis C [1] .
In HCV-monoinfected patients, the current reference treatment for chronic hepatitis C is pegylated interferon (PEG-IFN-a-2a) plus ribavirin [7, 8] . In HCV-HIVcoinfected patients, data concerning the virological efficacy of anti-HCV treatment are scarce. In 1999, when the present study was designed, PEG-IFN-a-2a was not available. However, the pharmacokinetic characteristics of a daily administration of interferon were expected to resemble closely those provided by PEG-IFN-a-2a. Also, ribavirin, a guanosine nucleoside analogue, was reported to inhibit the intracellular phosphorylation of zidovudine, stavudine, and zalcitabine in vitro [1, 9, 10] , but no data were available concerning in vivo interactions and their potential consequences in patients receiving HAART.
Because conventional IFN-ribavirin therapy was shown to yield an undetectable HCV load 24 weeks after completion of the treatment regimen in only 38% of HCV-monoinfected patients [11] , we aimed to evaluate the efficacy and safety of an optimized IFN regimen, consisting of an initial loading dose followed by daily administration, in HIV-infected patients with chronic hepatitis C. To avoid a failure of antiretroviral therapy related to interactions between ribavirin and HAART, we decided to add ribavirin to IFN at week 16 of treatment only for patients who had not cleared HCV after 12 weeks of IFN treatment. By that time, these patients were considered not to have had a virological response and, from an ethical viewpoint, could receive combined IFN-ribavirin therapy.
PATIENTS AND METHODS

Study population.
Patients aged 18-65 years who had chronic hepatitis C and HIV-1 infection and who had not been previously treated with IFN or ribavirin were eligible for the study. Patients had detectable plasma HCV RNA levels and elevated serum alanine aminotransferase (ALT) levels (i.e., levels that were greater than the upper limit of the normal range) at least twice during the year before randomization. A liver biopsy finding confirming chronic hepatitis, regardless of whether cirrhosis was present, had to be available within a year before study entry. Patients had a CD4 cell count of 1250 cells/mL and a plasma HIV RNA level of !10,000 copies/mL (determined using Quantiplex HIV RNA 2.0; Bayer). Patients were not required to be receiving antiretroviral therapy, and all treatment regimens were allowed.
Patients were not included in the study if circulating hepatitis B surface antigen was present, if they actively abused alcohol (i.e., self-reported consumption of 140 g per day), if they had a hemoglobin level of !11 g/dL, if they had platelet and neutrophil levels of !70 g/L and !1.5 g/L, respectively, or if they had experienced an opportunistic infection р6 months before study entry. Patients who presented with evidence of decompensated liver disease (i.e., ascites, bleeding varices, hepatic encephalopathy, a serum albumin level of !35 g/L, and a prothrombin time of !70%), hepatocellular carcinoma, or other relevant disorders or risk factors, such as previous organ transplantation, a preexisting psychiatric condition, cardiovascular disease, poorly controlled diabetes or seizure disorders, hemoglobinopathy, or autoimmune disease, were not included in the study.
Study design. Our study was a French multicenter, openlabel, randomized, controlled trial. It was approved by the ethics committee of Bordeaux (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Bordeaux). All patients provided written informed consent and were centrally randomized to receive IFN-a-2a (Roféron; Produits Roche) for 48 weeks, either (1) at a dose of 6 MU administered subcutaneously 3 times per week for 24 weeks, followed by 3 MU given 3 times per week for 24 weeks (i.e., the conventional IFNa-2a dose); or (2) at a dose of 9 MU per day for 2 weeks, followed by 3 MU per day for 22 weeks, followed by 3 MU given 3 times per week for 24 weeks (i.e., the daily IFN-a-2a dose). The serum level of HCV RNA was detected using a second-generation RT-PCR assay (Cobas Amplicor HCV 2.0; Roche; lower limit of detection, 100 copies/mL). If HCV RNA was still detectable at week 12 of therapy, oral ribavirin (Produits Roche) was added at a dosage of either 1000 mg twice per day (for patients with a body weight of !75 kg) or 1200 mg twice per day (for those with a body weight of у75 kg) at week 16 and was administered through the end of treatment.
Patients were evaluated as outpatients at weeks 2 and 4 and every 4 weeks thereafter, until the end of the treatment period. Patients were subsequently observed at follow-up visits 60 and 72 weeks after the start of the study. CD4 cell counts, determined by flow cytometry (FACScalibur; Becton Dickinson), and plasma HIV RNA levels were evaluated every 3 months. HCV was genotyped at the beginning of the treatment period (Inno-LiPA HCV II; Innogenetics). The plasma HCV load (Cobas Amplicor HCV Monitor 2.0 quantitative assay; Roche Molecular Diagnostics; lower limit of detection, 1000 copies/ mL) was measured before and at week 4 of treatment. A liver biopsy was performed for all patients who accepted 24 weeks after the completion of anti-HCV treatment.
End points. The primary efficacy end point of our study was a sustained virological response, defined as an undetectable serum HCV RNA level 24 weeks after the end of treatment. Early virological response and end-of-treatment virological response, defined as undetectable HCV RNA levels at weeks 12 and 48 of treatment, respectively, were secondary end points. Biochemical response, defined as an ALT level that was less than the upper limit of normal, was also assessed.
Histological response to anti-HCV therapy was evaluated by comparing the findings of a first liver biopsy (performed before study entry) with the findings of a second one (performed 24 weeks after the end of treatment). Liver lesions, as determined by stage of fibrosis and grade of activity, were evaluated for each biopsy specimen by 2 experienced pathologists using the METAVIR scoring system [12] .
Statistical analyses and study termination. The initially calculated sample size of 148 patients (74 in each group) was based on a type I error (a) rate of 0.05 and a power of 80%, considering that a sustained virological response of 20% was expected in the conventional dose group and that an improvement of at least 20% in the daily IFN-a-2a dose group would be considered in favor of better efficacy. Enrollment started in April 1999 and stopped in July 2000. At that stage, only 68 patients were randomized: the possibility of instead receiving therapy with PEG-IFN plus ribavirin dramatically reduced the potential for inclusion in our study. After reviewing available information from the trial, the Data and Safety Monitoring Board recommended that enrollment be prematurely terminated and that all patients included in the trial be followed-up until week 72.
Analyses were conducted on an intention-to-treat basis, in which we considered missing data to be nonresponses. At weeks 48 and 72 of the study, comparisons of treatment responses between both groups were made using the x 2 test. Analysis of histological response included only patients who underwent both pre-and posttreatment biopsies. Within each group, changes of у1 point in the METAVIR score were compared using Yates' corrected x 2 test. Multivariate logistic regression was used to study the association between sustained virological response and patient characteristics.
Variables considered for univariate analyses were age (140 years vs. р40 years), sex, HCV genotype (1 or 4 vs. 2 or 3), median HCV RNA level at baseline (1 copies/mL vs. 6 7.15 ϫ 10 р copies/mL), estimated duration of HCV infection 6 7.15 ϫ 10 (115 years vs. р15 years), METAVIR score for liver fibrosis (F3 or F4 vs. F1 or F2), CD4 cell count before initial commencement of antiretroviral treatment (1200 cells/mL vs. р200 cells/ mL) and at study inclusion (1500 cells/mL vs. р500 cells/mL), stage of HIV infection (according to Centers for Disease Control and Prevention classification), and type of antiretroviral treatment received (therapy that contained a protease inhibitor [PI] vs. therapy that did not contain a PI). The decrease in the HCV load between study enrollment and week 4 of treatment (у3 log 10 copies/mL vs. !3 log 10 copies/mL) was also analyzed.
Variables included in multivariate models were those with P values of р.25. All reported P values are 2-tailed. Analyses were performed using the SAS/STAT computer program (SAS Institute).
RESULTS
Characteristics of the Patients
From April 1999 through June 2000, 31 patients were randomized to the conventional IFN-a-2a group, and 37 were randomized to the daily IFN-a-2a group. At baseline, the 2 groups were similar (table 1), except for CD4 cell count, which was slightly higher in the daily IFN-a-2a group.
All 68 patients started anti-HCV therapy. Treatment was completed by 28 patients in the conventional IFN-a-2a group and 32 in the daily IFN-a-2a group. Follow-up was completed by 27 and 32 patients, respectively.
Virological Response
Overall, at week 12 of treatment, early virological response was achieved in 14 patients (21%), with no statistical difference between the 2 groups (table 2). All 49 patients who did not clear the virus at week 12 of treatment started receiving ribavirin. By week 48, 15 patients (22%) had end-of-treatment virological response. By week 72, sustained virological response was achieved in 10 patients (15%; 6 patients in the conventional IFN-a-2a group and 4 in the daily IFN-a-2a group) who were infected with genotype 3 (7 patients) or 1 (3 patients); 3 of these patients received combined IFN-a-2a plus ribavirin therapy. Differences between groups with regard to early, end-oftreatment, and sustained virological response did not reach statistical significance.
Biochemical Response
At week 72 of the study, 20 patients (29%) had normalized their ALT concentrations (table 2) . Among them, 11 were infected with HCV genotype 1 or 4, and 9 were infected with HCV genotype 2 or 3. ALT levels had already normalized by week 48 (end of treatment) in 26 patients (38%). All 10 patients with sustained virological response also had normalization of their ALT levels. Among the 49 patients who did not have a virological response at week 72, the ALT concentration had normalized in 10 patients (3 of 21 in the conventional IFN-a-2a group and 7 of 28 in the daily IFN-a-2a group). There was no statistically significant difference between treatment groups.
Histological Response
Paired pre-and posttreatment biopsy samples were available for only 31 patients (18 in the conventional IFN-a-2a group and 13 in the daily IFN-a-2a group); the other patients refused to undergo a second biopsy. Among 4 patients with sustained virological response for whom both biopsy samples were available, liver fibrosis improved in 2, was stable in 1, and worsened in 1; activity improved in 3 of these patients and was stable in 1. Among the 27 patients who did not clear the virus at week 72 and for whom both biopsy samples were available, liver fibrosis improved in 7 (26%), remained unchanged in 13 (48%), and worsened in 7 (26%); activity improved in 15 (56%) of these patients, was stable in 8 (30%), and worsened in 4 (15%).
Factors Associated with Sustained Virological Response
Sustained virological response was unrelated to age or sex. Infection with HCV genotype 2 or 3 was associated with a sustained virological response (7 of 10 of those infected with HCV genotype 2 or 3 vs. 20 of 58 of those infected with HCV genotype 1 or 4;
), whereas baseline HCV load was not. P p .03 No association with a sustained virological response was found for either factors related to HIV infection (such as nadir and baseline CD4 cell counts) or for receipt of treatment with protease inhibitors. In the multivariate logistic regression model, the only factor that remained independently associated with a sustained virological response was HCV genotype (OR for genotype 2 or 3 vs. 1 or 4, 6.84; 95% CI, 1.40-33.40; ). P p .02 Although no association was found between the initial HCV RNA level and sustained virological response, a decrease of у3 log 10 in the HCV RNA level between the beginning and week 4 of anti-HCV treatment was significantly associated with sustained virological response (OR, 52.49; 95% CI, 4.50-612.98;
). P p .002
Clinical and Laboratory Toxicity Associated with Anti-HCV Therapy
Overall, 16 patients (24%; 7 in the conventional IFN-a-2a group and 9 in the daily IFN-a-2a group) did not complete the treatment regimen because of adverse events. For the same reason, doses of IFN-a-2a or ribavirin were reduced in 21 patients. No deaths were reported during the follow-up period.
Severe (grade 3 or 4) clinical and biological adverse events are shown in table 3. The frequency of clinical events was not different between treatment groups. The most frequent side effects were flulike and neurological symptoms. None of the 6 patients who experienced neurological adverse events received efavirenz concomitantly. Twelve severe hematological adverse events were reported. Six of 9 patients with neutropenia received zidovudine simultaneously. Severe anemia occurred in 3 patients in the conventional IFN-a-2a group at weeks 16, 30, and 46 of the study. These 3 patients were receiving zidovudine, and none of them had received ribavirin. Finally, for 5 patients, a severe elevation in the ALT level (15 times the upper limit of normal) obligated modification of the anti-HCV treatment.
Evolution of Markers of HIV Disease
CD4 cell count. In the conventional IFN-a-2a group, the median CD4 count decreased from the time of study entry (491 cells/mL; range, 300-961 cells/mL) to its lowest value at week 48 (402 cells/mL; range, 216-616 cells/mL), and it returned to the baseline level at week 72 (478 cells/mL; range, 127-960 cells/ mL). In the daily IFN-a-2a group, the median CD4 count was 578 cells/mL (range, 269-1644 cells/mL) at baseline and decreased to its lowest value at week 2, after receipt of the loading dose (448 cells/mL; range, 138-947 cells/mL). It was at a plateau through week 48 (453 cells/mL; range, 128-1013 cells/mL) and was higher than baseline at week 72 (562 cells/mL; range, 182-2500 cells/mL). At week 24, the CD4 percentage increased from 28.2% and 26.0% at baseline to 28.8% (range, 12%-44.6%) and 34.0% (range, 17.5%-48.1%) in the conventional IFN-a-2a and daily IFN-a-2a groups, respectively. Thereafter, the percentages returned to baseline values.
Plasma HIV RNA level. Overall, the proportion of patients with undetectable plasma HIV RNA levels did not differ significantly at the initiation of anti-HCV therapy (49%) from that observed at the end of the follow-up period (37%). Seven patients had an increase in the plasma HIV RNA level of у0.5 log 10 copies/ mL between study entry and week 72. Two patients discontinued antiretroviral treatment because of side effects, and 3 received 2 antiretroviral drugs each. For the other 2 patients, compliance with antiretroviral treatment was uncertain.
DISCUSSION
Our results show a low rate of response to anti-HCV therapy in HIV-HCV-coinfected patients and no difference in the efficacy between the 2 regimens of IFN-a-2a. The lack of power in our study resulting from its early termination is a serious limitation. However, the average difference in sustained virological response between both groups (8.6%, in favor of the conventional IFN-a-2a group) is far from reaching the anticipated 20% difference in favor of the daily IFN-a-2a group considered for the initial calculation of the sample size.
In HCV-HIV-coinfected patients, the efficacy of anti-HCV treatment is as yet undetermined. Studies that have investigated the efficacy of IFN-a-2a monotherapy were conducted with small numbers of patients, showing important variations in the rates of sustained virological response (0%-44% after 6-12 months of IFN-a-2a therapy) [13] . Overall, response to IFNa-2a was estimated to be similar in immunocompetent and HCV-HIV-coinfected patients [1, [14] [15] [16] . However, sustained virological response was observed in only 17% of HCV-HIVcoinfected patients, and the percentage could be even smaller among patients with low CD4 cell counts [17] . Data on the efficacy of IFN-a-2a-ribavirin combinations are still scarce. Sustained virological response was reported for 25% of 198 patients treated with IFN-a-2a plus ribavirin [1] . In a study that evaluated the efficacy of combined therapy for 51 patients with severe chronic hepatitis C, sustained virological response was achieved in 21% of the patients [18] . Recently, the efficacy of the combination of PEG-IFN and ribavirin was compared with that of conventional IFN-a-2a plus ribavirin. An end-oftreatment virological response was obtained in 15% of the patients treated with the second regimen [19] . The virological response rate obtained in our study was disappointing when we consider that the patients had a satisfactory immune status and that IFN-a-2a was administered daily. The loading dose was expected to induce a rapid decrease in the HCV load. Indeed, a 3-log 10 decrease after 4 weeks of therapy has been shown to be predictive of a sustained response in immunocompetent patients [20] . In our study, the delayed addition of ribavirin, which was also proposed by Sauleda et al. [21] 1 month after the beginning of IFN-a-2a therapy, may have had a negative effect on the response.
HCV genotype is a critical prognostic factor for virological response in immunocompetent and HCV-HIV-coinfected patients [18, 22] . HCV genotypes 2 and 3 were associated with virological response in our study. Furthermore, an early decrease in the HCV load was predictive of sustained virological response. Age, female sex, minimal fibrosis, and serum HCV RNA level at baseline, which have been reported to be independent factors for response in immunocompetent patients [22] , were not associated with treatment efficacy in our study. Factors that were related to HIV infection and predictive of sustained virological response to anti-HCV therapy, such as CD4 cell counts of 1500 cells/mL or HIV RNA levels of !10,000 copies/mL, have also been proposed elsewhere [1, 14] . However, we did not observe such associations, possibly because of the small sample size.
In HIV-negative patients, therapy with IFN alone or combined with ribavirin may improve liver fibrosis, even in the absence of virological response [23] . Histological improvement after receipt of IFN was demonstrated to be as frequent in HIVnegative patients as in HCV-HIV-coinfected patients [24] . To our knowledge, no data have been reported for HCV-HIVcoinfected patients treated with IFN-a-2a and ribavirin. In our study, posttreatment liver biopsy findings were available mainly for persons without virological response. Fibrosis was unchanged or improved in 76% of the patients but worsened in 24%. This proportion was almost similar for 32 HCV-HIVcoinfected patients treated with IFN-a-2a for whom virological response was unknown [24] . If studies confirm that anti-HCV therapy is less effective for HCV-HIV-coinfected patients, a definition of factors associated with histological response might be crucial.
In our study, overall tolerance to IFN-a-2a and ribavirin therapy did not differ from that reported elsewhere for HIV-negative patients. Hematological tolerance was poor in our study, espe-cially in patients who received daily doses of IFN-a-2a. Because of cumulative toxicity, antiretroviral treatment that includes zidovudine, which also favors the occurrence of neutropenia or anemia, must be avoided or carefully monitored. Similarly, efavirenz may favor neuropsychiatric IFN-a-2a-related complications. A potential risk of lactic acidosis associated with the use of ribavirin and purine nucleoside analogue reverse-transcriptase inhibitors has been reported [1, 25] . Such a complication was not observed in our study. Reports from before the HAART era described persistent IFN-a-2a-induced lymphopenia in HIVinfected patients with chronic hepatitis C [14] . Our results confirm that anti-HCV treatment has no detrimental effect on longterm CD4 cell count [18, 21] . Finally, results of HIV plasma load monitoring do not argue for the existence of in vivo interactions between ribavirin and antiretroviral drugs [26, 27] .
In conclusion, in our study, the combination of IFN-a-2a and ribavirin appears to have a poor virological efficacy in HCV-HIV-coinfected patients, although this result needs to be confirmed by larger trials. 
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